Neuberger Berman Group’s Beam Therapeutics BEAM Stock Holding History

Neuberger Berman Group’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-39,132	Closed	-$1.25M	–	1816
2023 Q2	$1.25M	Buy	39,132 +8,351	+27%	+$271K	﹤0.01%	1188
2023 Q1	$943K	Buy	30,781 +1,089	+4%	+$43K	﹤0.01%	1269
2022 Q4	$1.16M	Buy	29,692 +7,343	+33%	+$329K	﹤0.01%	1201
2022 Q3	$1.06M	Sell	22,349 -72	-0.3%	-$4.11K	﹤0.01%	1238
2022 Q2	$868K	Sell	22,421 -208	-0.9%	-$8.27K	﹤0.01%	1325
2022 Q1	$1.3M	Sell	22,629 -3,900	-15%	-$256K	﹤0.01%	1289
2021 Q4	$2.07M	Sell	26,529 -4	-0%	-$342	﹤0.01%	1183
2021 Q3	$2.26M	Buy	26,533 +725	+3%	+$72.8K	﹤0.01%	1135
2021 Q2	$3.32M	Buy	+25,808	New	+$2.06M	﹤0.01%	1059

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Neuberger Berman Group's BEAM Position: Q3 2023 in Review

Neuberger Berman Group sold out of Beam Therapeutics (BEAM) in Q3 2023, closing a stake of 39,132 shares — an estimated $1.25M sold.

Neuberger Berman Group first reported a position in BEAM in Q2 2021 and held it in 9 quarters. The position peaked at $3.32M in Q2 2021. 194 funds tracked by Wall St. Rank hold BEAM as of Q3 2023.

Neuberger Berman Group reported no remaining Beam Therapeutics position as of Q3 2023 after selling out during the quarter.
Neuberger Berman Group sold 39,132 Beam Therapeutics shares in Q3 2023, an estimated $1.25M.
Neuberger Berman Group first reported a position in Beam Therapeutics in Q2 2021 and held it in 9 quarters.
Neuberger Berman Group's Beam Therapeutics position peaked at $3.32M in Q2 2021.
194 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2023.

Based on Neuberger Berman Group's 13F filing for Q3 2023, filed 14 Nov 2023.